University College London

Orchard Therapeutics launches, partners on transformative gene therapies

Monday, May 9, 2016

Orchard Therapeutics, a clinical-stage biotechnology company with operations in London and the U.S., has officially launched with a £21-million Series A financing led by F-Prime Capital. As part of its launch, the company has announced formal partnerships with University College London (UCL), Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), the University of Manchester, the University of California Los Angeles (UCLA) and Boston Children’s Hospital for the development of transformative gene therapies for serious and life-threatening orphan diseases.

[Read More]

UCL launches $55M technology investment fund

Wednesday, January 20, 2016

UCL is launching the UCL Technology Fund to invest £50 million ($55 million) in commercializing its research emerging over the next five years. The Fund will be used to support academics whose research has commercial potential, with funding for early stage proof-of-concept, licensing projects and new spinout companies.

[Read More]

MRC, GSK, five U.K. universities collaborate on difficult disease areas

Wednesday, July 15, 2015

Medical Research Council (MRC), GlaxoSmithKline and five U.K. universities are collaborating on difficult disease areas. The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network will be coordinated by University College London (UCL) and will bring together teams of researchers from the Universities of Cambridge, Glasgow, Newcastle, Imperial College London and UCL with GSK researchers to study the fundamental biological mechanisms responsible for a range of inflammatory diseases.

[Read More]

Vtesse forms scientific advisory board

Friday, March 27, 2015

Vtesse, a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases with great unmet need, has formed its scientific advisory board (SAB). Comprising experts from a range of fields including pediatrics, translational medicine, biomarker research and genetics, the SAB will advise on clinical and regulatory strategy as well as product development for the company’s lead candidate, VTS-270.

[Read More]

Alzheimer’s Research U.K. launches three Drug Discovery Institutes

Wednesday, February 18, 2015

Alzheimer’s Research U.K., a dedicated dementia research charity, has announced a $46.3 million Drug Discovery Alliance, launching three flagship Drug Discovery Institutes at the Universities of CambridgeOxford and University College London (UCL). The Drug Discovery Institutes will see 90 new research scientists employed in state-of-the-art facilities to fast-track the development of new treatments for Alzheimer’s disease and other dementias.

[Read More]